Core Insights - Tongce Medical (600763) reported a slight decline in stock price, closing at 42.2 yuan, with a trading volume of 31,600 shares and a total transaction value of 134 million yuan on October 22, 2025 [1] Trading Information Summary - On October 22, 2025, the net outflow of main funds was 929,100 yuan, accounting for 0.69% of the total transaction value; retail investors had a net inflow of 3.21 million yuan, representing 2.4% of the total transaction value [1][3] Company Announcement Summary - Tongce Medical held a semi-annual performance briefing on October 22, 2025, reporting the following key financial metrics for the first half of 2025: - Outpatient visits reached 1.7322 million, a year-on-year increase of 1.21% - Revenue was 1.448 billion yuan, up 2.68% year-on-year - Net profit attributable to shareholders was 321 million yuan, reflecting a 3.67% increase year-on-year - Net profit excluding non-recurring items was 317 million yuan, with a year-on-year growth of 3.9% - Operating cash flow net amount was 355 million yuan, up 9.7% year-on-year - Medical service revenue in Zhejiang Province was 1.22 billion yuan, a 2.6% increase year-on-year - Gross margin was 40.75%, and net margin was 26.26% - Orthodontics business grew by 7.75%, while pediatric services accounted for 17.6% of total revenue - Revenue from Loudi Dental Hospital increased by 7% year-on-year - The company has completed supply chain integration, leading to a continuous decrease in material costs - A new branch in Shanghai is expected to open by the end of the year, with plans to establish five new branches in 2025 - High labor costs are being managed through the development of a physician training program and improved diagnostic efficiency [1]

证券代码：600763 证券简称：通策医疗 编号：临 2025-029 通策医疗股份有限公司 关于 2025 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"）2025年半年度业绩说明会(以下 简称"说明会")于2025年10月22日（星期三）15:00-16:00于上海证券交易所上 证路演中心网络互动方式召开。公司董事长兼总经理王毅女士、董事会秘书张华 先生、财务总监徐国喜先生等出席本次说明会，与投资者进行沟通和交流，投资 者交流的主要问题及回复概要如下： 1.2025年半年度的业绩情况说明。 机构与人员规模：公司旗下共有 89 家医疗机构，拥有专业医疗人员 4452 名，营业面积超过 26 万平方米，开设牙椅 3100 余台。 核心经营数据：上半年口腔医疗门诊人次达 173.22 万人次，同比增长 1.21%； 实现总营业收入 14.48 亿元，同比增长 2.68%，其中医疗服务收入 13.45 亿元， 同比增长 2.3%。实现归母净利润 3.2 ...

Core Insights - The company acknowledges recent operational difficulties faced by some dental clinics in the market, attributing this to both short-term environmental challenges and the inevitable process of industry standardization and consolidation [1] Company Overview - As of the first half of 2025, the company operates 89 dental medical institutions and plans to establish 5 new branches in the coming years [1] - The company intends to proceed with the construction and opening of these new branches steadily, aligning with market conditions and its own development pace [1]

| | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净洗火 波户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-21 | 42.27 0.74% | 49.83万 | 0.31% | -1077.04万 | -6.79% | 1027.21万 | - 6.48% | | 2025-10-20 | 41.96 0.02% | -1791.90万 | -10.91% | -147.65万 | -0.90% | 1939.55万 | 11.81% | | 2025-10-17 | 41.95 -2.96% | -5398.63万 | -18.18% | 791.02万 | 2.66% | 4607.61万 | 15.52% | | 2025-10-16 | 43.23 -1.37% | -2113.84万 | -9.01% | 679.35万 | 2.90% | 1434.50万 | 6.11% | | 2025-10-15 | 43.83 0.90% | -702.93万 | -3.61% ...

Core Viewpoint - Tongce Medical (600763) experienced a decline in stock price, closing at 41.95 yuan on October 17, 2025, down 2.96% with significant net outflow of main funds [1][2] Fund Flow Summary - On October 17, 2025, main funds had a net outflow of 53.99 million yuan, accounting for 18.18% of total trading volume, while retail investors saw a net inflow of 46.08 million yuan, representing 15.52% of total trading volume [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with the highest net outflow of main funds recorded on October 17, 2025, at 53.99 million yuan [2] Company Performance Metrics - As of the latest report, Tongce Medical's total market value is 18.764 billion yuan, with a net asset value of 4.467 billion yuan and a net profit of 321 million yuan [3] - The company reported a year-on-year revenue increase of 2.68% to 1.448 billion yuan and a net profit increase of 3.67% to 321 million yuan for the first half of 2025 [3] - The company's gross margin stands at 40.75%, significantly higher than the industry average of 35.92%, and its net profit margin is 26.26%, compared to the industry average of 3.8% [3] Industry Ranking - Tongce Medical ranks 8th in total market value and 12th in net assets within the medical services industry, with a price-to-earnings ratio of 29.21, which is significantly lower than the industry average of 82.41 [3] - The company has received 9 ratings from institutions in the last 90 days, with 7 buy ratings and 2 hold ratings, and the average target price set at 52.01 yuan [4]

Core Viewpoint - Tongce Medical (600763) shows a slight increase in stock price and mixed capital flow, indicating potential investor interest despite some outflows from major funds [1][2]. Financial Performance - As of the latest report, Tongce Medical's total revenue for the first half of 2025 reached 1.448 billion yuan, a year-on-year increase of 2.68% [3]. - The net profit attributable to shareholders was 321 million yuan, up 3.67% year-on-year, while the net profit excluding non-recurring items was 317 million yuan, increasing by 3.85% [3]. - The company's second-quarter revenue was 704 million yuan, reflecting a 0.24% year-on-year growth, with a net profit of 137 million yuan, up 0.44% year-on-year [3]. Market Position - Tongce Medical's total market capitalization is 19.605 billion yuan, ranking 8th in the medical services industry [3]. - The company has a price-to-earnings ratio of 30.52, significantly lower than the industry average of 83.4, indicating a potentially undervalued stock [3]. - The gross margin stands at 40.75%, higher than the industry average of 35.92%, showcasing operational efficiency [3]. Capital Flow Analysis - On October 15, 2025, the stock experienced a net outflow of 7.0293 million yuan from major funds, accounting for 3.61% of the total transaction volume [2]. - Retail investors contributed a net inflow of 1.8809 million yuan, representing 0.97% of the total transaction volume, indicating some retail interest [1][2]. Analyst Ratings - Over the past 90 days, 9 institutions have rated the stock, with 7 buy ratings and 2 hold ratings, suggesting a generally positive outlook [4]. - The average target price set by analysts is 5.201 yuan, indicating potential upside from the current trading price [4].

证券代码：600763 证券简称：通策医疗 公告编号：2025-028 通策医疗股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/）； 通策医疗股份有限公司（以下简称"公司"）已于 2025 年 8 月 23 日发布公 司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度 经营成果、财务状况，公司计划于 2025 年 10 月 22 日（星期三）15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 10 月 22 日（星期三）15:00-16:00； 1 会议召开时间：20 ...

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry [2][24]. Core Viewpoints - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, declining by 0.23% from September 26, 2025, to October 9, 2025, lagging behind the index by approximately 2.76 percentage points [9][24]. - Most sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and in vitro diagnostics sectors showing gains of 1.99% and 0.55%, respectively, while the raw materials and chemical preparations sectors fell by 2.23% and 1.73% [10][24]. - Approximately 54% of stocks in the industry achieved positive returns, with the top performer, Zhendemedical, increasing by 21.43%, while the largest decline was seen in Guangshentang, which fell by 21.86% [11][14]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 55.04 times as of October 9, 2025, indicating a decrease in industry valuation [15][24]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.23% from September 26, 2025, to October 9, 2025 [9]. - Most sub-sectors recorded negative returns, with medical research outsourcing and in vitro diagnostics performing better than others [10]. - About 54% of stocks in the industry recorded positive returns, with significant variations in individual stock performance [11]. 2. Industry News - The 11th batch of national procurement will begin accepting applications on October 21, 2025, with 55 major varieties included [22]. - The National Medical Products Administration issued guidelines for the quality management of medical device online sales [20][21]. 3. Company Announcements - Zhejiang Haizheng Pharmaceutical announced that its product achieved Self-GRAS certification in the U.S., allowing it to enter the U.S. market [23]. 4. Weekly Industry Perspective - The report suggests focusing on investment opportunities in innovative drugs and sectors with expected business development catalysts, including medical devices and pharmaceutical commerce [24][26].

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Group 1 - The announcement details the stock pledge and release of shares by the controlling shareholder, Hangzhou Baoqun Industrial Group Co., Ltd. (referred to as "Baoqun Industrial") [2][3] - Baoqun Industrial holds a total of 151,589,199 shares in Tongce Medical Co., Ltd., accounting for 33.89% of the total share capital [2] - The pledged shares amount to 2,250,000, which is 1.48% of Baoqun Industrial's holdings and 0.50% of the total shares of the company; simultaneously, 2,871,219 shares were released from pledge [2] Group 2 - The total number of pledged shares by Baoqun Industrial is 98,476,672, representing 64.96% of its holdings and 22.02% of the total shares of the company [2] - The controlling shareholder has 31,470,000 shares due for pledge in the next six months, which is 20.76% of its holdings and 7.04% of the total share capital; in the next year, 86,586,672 shares are due, accounting for 57.12% of its holdings and 19.36% of the total shares [4] - Baoqun Industrial's credit status is good, and it has the ability to repay, indicating that the pledge risk is controllable and will not affect the company's main business or operational capability [5]